Zacks Investment Research upgraded shares of DBV Technologies S.A. (NASDAQ:DBVT) from a hold rating to a buy rating in a report released on Tuesday. Zacks Investment Research currently has $49.00 target price on the stock.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
DBVT has been the topic of a number of other research reports. HC Wainwright reaffirmed a buy rating and issued a $50.00 target price on shares of DBV Technologies in a research note on Thursday, July 6th. BidaskClub raised DBV Technologies from a strong sell rating to a sell rating in a research note on Wednesday, June 21st. Deutsche Bank AG began coverage on DBV Technologies in a research note on Friday, June 23rd. They issued a buy rating and a $46.00 target price on the stock. ValuEngine raised DBV Technologies from a sell rating to a hold rating in a research note on Saturday, June 24th. Finally, Jefferies Group LLC reaffirmed a buy rating on shares of DBV Technologies in a research note on Thursday, August 31st. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $50.50.
DBV Technologies (DBVT) opened at 43.97 on Tuesday. DBV Technologies has a 12 month low of $31.87 and a 12 month high of $46.33. The stock’s market cap is $2.02 billion. The company’s 50-day moving average price is $44.12 and its 200-day moving average price is $37.54.
WARNING: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/2888445/dbv-technologies-s-a-dbvt-upgraded-to-buy-at-zacks-investment-research.html.
Several institutional investors have recently modified their holdings of DBVT. DekaBank Deutsche Girozentrale purchased a new position in shares of DBV Technologies during the 1st quarter worth $471,000. Parametric Portfolio Associates LLC lifted its stake in shares of DBV Technologies by 9.2% during the 1st quarter. Parametric Portfolio Associates LLC now owns 33,270 shares of the company’s stock worth $1,172,000 after purchasing an additional 2,794 shares during the period. Victory Capital Management Inc. purchased a new position in shares of DBV Technologies during the 1st quarter worth $303,000. Sphera Funds Management LTD. lifted its stake in shares of DBV Technologies by 14.1% during the 1st quarter. Sphera Funds Management LTD. now owns 90,167 shares of the company’s stock worth $3,176,000 after purchasing an additional 11,109 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in shares of DBV Technologies by 21.1% during the 1st quarter. Alliancebernstein L.P. now owns 996,535 shares of the company’s stock worth $35,098,000 after purchasing an additional 173,798 shares during the period. 45.52% of the stock is currently owned by institutional investors.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.